medigraphic.com
Centro de Investigaciones Regionales Dr. Hideyo Noguchi, Universidad Autónoma de Yucatán

2023, Number 2

<< Back Next >>

Rev Biomed 2023; 34 (2)

COVID-19 during the third wave in Mexico: symptoms and vaccination as protective factor in Durango

Olivas-Calderón E, García-Alvarado FJ, Delgado-Aguirre HA, Facio-Campos RA

Language: English
References: 17
Page: 245-250
PDF size: 128.04 Kb.


ABSTRACT

Introduction. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was responsible for the pandemic Coronavirus Disease 2019 (COVID-19) declared in March 2020. Worldwide, vaccination against SARS-CoV-2 has been very important.
Objective. To evaluate the frequency of the infection of SARS-CoV-2, symptoms related to the infection and the impact of vaccination.
Materials and Methods. From October 2021 to January 2022 917 subjects were evaluated. SARSCoV- 2 was diagnosed by RT-PCR.
Results. The total incidence of positive cases was 41.66% (n = 382). Previous application of the vaccine and being in contact with positive subjects 14 days prior to diagnosis deliver a protective with regard the virus (OR = 0.60 and 0.50, respectively) (p ‹0.05).
Discussion. We observed an association between fever, cough, anosmia, and dysgeusia with the infection, which corresponds to what has been reported in the literature, as well as a protective factor attributable to vaccination, as expected.
Conclusion. The vaccine against SARS-CoV-2 is effective, regardless of the manufacturer.


REFERENCES

  1. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al.A novel coronavirus from patients with pneumonia inChina, 2019. N Engl J Med. 2020;382(8):727-33. doi:10.1056/NEJMoa2001017.

  2. Dirección General de Información en Salud. COVID-19,México: Datos epidemiológicos: México: SINAVE2020; 2022. Available at: https://covid19.sinave.gob.mx/

  3. Cui J, Li F, Shi Z-L. Origin and evolution of pathogeniccoronaviruses. Nat Rev Microbiol. 2019;17(3):181-92.doi: 10.1038/s41579-018-0118-9.

  4. Lechien JR, Chiesa-Estomba CM, De Siati DR, Horoi M,Le Bon SD, Rodríguez A, et al. Olfactory and gustatorydysfunctions as a clinical presentation of mild-tomoderateforms of the coronavirus disease (COVID-19):a multicenter European study. Eur Arch Oto-Rhino-L.2020;277(8):2251-61. doi: 10.1007/s00405-020-05965-1.

  5. Saniasiaya J, Islam MA, Abdullah B. Prevalence ofolfactory dysfunction in coronavirus disease 2019(COVID-19): a meta-analysis of 27,492 patients.Laryngoscope. 2021;131(4):865-78. doi: 10.1002/lary.29286.

  6. Johansson MA, Quandelacy TM, Kada S, Prasad PV,Steele M, Brooks JT, et al. SARS-CoV-2 Transmissionfrom people without COVID-19 symptoms. JAMANetw Open. 2021;4(1): e2035057-e. doi: 10.1001/jamanetworkopen.2020.35057.

  7. Dirección General de Epidemiología. Manual deprocedimientos estandarizados para la vigilanciaepidemiológica convencional. Secretaría de Salud.México. (2021). Available: https://epidemiologia.salud.gob.mx/gobmx/salud/documentos/manuales/32_ManualSuive.pdf.

  8. World Health Organization. Laboratory testing forcoronavirus disease (COVID-19) in suspected humancases Interim guidance 19 March 2020. Available:https://wwwwhoint/publications-detail/laboratorytesting-for2019-novel-coronavirus-in-suspected-humancases-20200117.

  9. Fernández-Rojas MA, Luna-Ruiz Esparza MA, Campos-Romero A, Calva-Espinosa DY, Moreno-Camacho JL,Mendlovic F, et al. Seroconversion dynamic and SARSCoV-2 seropositivity in unvaccinated population duringthe first and second outbreaks in Mexico. Sci Rep.2022;12(1):5241. doi: 10.1038/s41598-022-09395-3.

  10. Covantes-Rosales CE, Barajas-Carrillo VW, Girón-Pérez DA, Toledo-Ibarra GA, Díaz-Reséndiz KJG,Navidad-Murrieta MS, et al. Comparative analysis ofage, sex, and viral load in outpatients during the fourwaves of SARS-CoV-2 in a Mexican medium-sized city.Int J Environ Res Public Health. 2022;19(9): 5719. doi:10.3390/ijerph19095719.

  11. Núñez I, Caro-Vega Y, Belaunzarán-Zamudio PF.Diagnostic precision of local and World HealthOrganization definitions of symptomatic COVID-19cases: an analysis of Mexico’s capital. Public Health.2022; 205:187-91. doi: 10.1016/j.puhe.2022.02.010.

  12. Anaya-Covarrubias JY, Pizuorno A, Mirazo S, Torres-Flores J, Du Pont G, Lamoyi E, et al. COVID-19 inLatin America and the Caribbean region: symptoms andmorbidities in the epidemiology of infection. COPHAR.2022; 63:102203. doi: 10.1016/j.coph.2022.102203.

  13. Carnalla M, Basto-Abreu A, Stern D, Bautista-Arredondo S, Shamah-Levy T, Alpuche-Aranda CM,et al. Acceptance, refusal and hesitancy of Covid-19vaccination in Mexico: Ensanut 2020 Covid-19. SaludPubl Mex. 2021;63(5):598-606. doi: 10.21149/12696.

  14. Monge S, Rojas-Benedicto A, Olmedo C, Martín-MerinoE, Mazagatos C, Limia A, et al. Effectiveness of asecond dose of an mRNA vaccine against SARS-CoV-2Omicron infection in individuals previously infectedby other variants. Clin Infect Dis. 2022; ciac429. doi:10.1093/cid/ciac429.

  15. Cueto-Robledo G, Navarro-Vergara D-I, Roldán-ValadezE, Garía-César M, Graniel-Palafox L-E, Cueto-RomeroH-D, et al. Pulmonary embolism (PE) prevalence inMexican-mestizo patients with severe SARS-COV-2(COVID-19) pneumonia at a tertiary-level hospital: areview. Curr Probl Cardiol. 2022:101208. doi: 10.1016/j.cpcardiol.2022.101208.

  16. Chu DK, Akl EA, Duda S, Solo K, Yaacoub S,Schunemann H. Physical sistancing, face masks, and eyeprotection to prevent person-to-person Transmission ofSARS-CoV-2 and COVID-19: a systematic review andmeta-analysis. Lancet. 2020; 395(10242), 1973–1987.doi: 10.1016/S0140-6736(20)31142-9.

  17. Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ,Prescott HC. Pathophysiology, transmission, diagnosis,and treatment of Coronavirus Disease 2019 (COVID-19):a review. Jama. 2020;324(8):782-93. doi: 10.1001/jama.2020.12839.




2020     |     www.medigraphic.com